CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/91889
Title:
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.
Authors:
Lundin, J; Osterborg, Anders; Brittinger, G; Crowther, Derek; Dombret, Herve; Engert, Andreas; Epenetos, A; Gisselbrecht, Christian; Huhn, D; Jaeger, U; Thomas, J; Marcus, Robert; Nissen, N; Poynton, C; Rankin, Elaine M; Stahel, R; Uppenkamp, M; Willemze, R; Mellstedt, H
Abstract:
PURPOSE: CAMPATH-1H is a human immunoglobulin G1 (IgG1) anti-CD52 monoclonal antibody (MAb) that binds to nearly all B-cell and T-cell lymphomas. We report here the results of a multicenter phase II trial of CAMPATH-1H in patients with advanced, low-grade non-Hodgkin's lymphoma (NHL) who were previously treated with chemotherapy. PATIENTS AND METHODS: Fifty patients who had relapsed (n=25) after or were resistant (n = 25) to chemotherapy were treated with CAMPATH-1H 30 mg administered as a 2-hour intravenous (i.v.) infusion three times weekly for a maximum period of 12 weeks. RESULTS: Six patients (14%) with B-cell lymphomas achieved a partial remission (PR). Patients with mycosis fungoides appeared to respond more frequently (50%; four of eight patients, which included two complete remissions [CRs]). Lymphoma cells were rapidly eliminated from blood in 16 of 17 patients (94%). CR in the bone marrow was obtained in 32% of the patients. Lymphoma skin lesions disappeared completely in four of 10 patients and partial regression was obtained in three patients. Lymphadenopathy and splenomegaly were normalized in only 5% and 15% of patients, respectively. Lymphopenia (< 0.5 x 10(9)/L) occurred in all patients. World Health Organization (WHO) grade IV neutropenia occurred in 14 patients (28%). Opportunistic infections were diagnosed in seven patients and nine patients had bacterial septicemia. Death related to infectious complications occurred in three patients. CONCLUSION: CAMPATH-1H had a significant but limited activity in patients with advanced, heavily pretreated NHL. The most pronounced effects were noted in the blood and bone marrow and in patients with mycosis fungoides. The risk for serious infectious complications needs to be considered for severely ill patients who are evaluated for CAMPATH-1H treatment.
Affiliation:
Department of Oncology, Karolinska Hospital, Stockholm, Sweden.
Citation:
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. 1998, 16 (10):3257-63 J. Clin. Oncol.
Journal:
Journal of Clinical Oncology
Issue Date:
Oct-1998
URI:
http://hdl.handle.net/10541/91889
PubMed ID:
9779699
Type:
Article
Language:
en
ISSN:
0732-183X
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorLundin, Jen
dc.contributor.authorOsterborg, Andersen
dc.contributor.authorBrittinger, Gen
dc.contributor.authorCrowther, Dereken
dc.contributor.authorDombret, Herveen
dc.contributor.authorEngert, Andreasen
dc.contributor.authorEpenetos, Aen
dc.contributor.authorGisselbrecht, Christianen
dc.contributor.authorHuhn, Den
dc.contributor.authorJaeger, Uen
dc.contributor.authorThomas, Jen
dc.contributor.authorMarcus, Roberten
dc.contributor.authorNissen, Nen
dc.contributor.authorPoynton, Cen
dc.contributor.authorRankin, Elaine Men
dc.contributor.authorStahel, Ren
dc.contributor.authorUppenkamp, Men
dc.contributor.authorWillemze, Ren
dc.contributor.authorMellstedt, Hen
dc.date.accessioned2010-02-11T16:42:44Z-
dc.date.available2010-02-11T16:42:44Z-
dc.date.issued1998-10-
dc.identifier.citationCAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. 1998, 16 (10):3257-63 J. Clin. Oncol.en
dc.identifier.issn0732-183X-
dc.identifier.pmid9779699-
dc.identifier.urihttp://hdl.handle.net/10541/91889-
dc.description.abstractPURPOSE: CAMPATH-1H is a human immunoglobulin G1 (IgG1) anti-CD52 monoclonal antibody (MAb) that binds to nearly all B-cell and T-cell lymphomas. We report here the results of a multicenter phase II trial of CAMPATH-1H in patients with advanced, low-grade non-Hodgkin's lymphoma (NHL) who were previously treated with chemotherapy. PATIENTS AND METHODS: Fifty patients who had relapsed (n=25) after or were resistant (n = 25) to chemotherapy were treated with CAMPATH-1H 30 mg administered as a 2-hour intravenous (i.v.) infusion three times weekly for a maximum period of 12 weeks. RESULTS: Six patients (14%) with B-cell lymphomas achieved a partial remission (PR). Patients with mycosis fungoides appeared to respond more frequently (50%; four of eight patients, which included two complete remissions [CRs]). Lymphoma cells were rapidly eliminated from blood in 16 of 17 patients (94%). CR in the bone marrow was obtained in 32% of the patients. Lymphoma skin lesions disappeared completely in four of 10 patients and partial regression was obtained in three patients. Lymphadenopathy and splenomegaly were normalized in only 5% and 15% of patients, respectively. Lymphopenia (< 0.5 x 10(9)/L) occurred in all patients. World Health Organization (WHO) grade IV neutropenia occurred in 14 patients (28%). Opportunistic infections were diagnosed in seven patients and nine patients had bacterial septicemia. Death related to infectious complications occurred in three patients. CONCLUSION: CAMPATH-1H had a significant but limited activity in patients with advanced, heavily pretreated NHL. The most pronounced effects were noted in the blood and bone marrow and in patients with mycosis fungoides. The risk for serious infectious complications needs to be considered for severely ill patients who are evaluated for CAMPATH-1H treatment.en
dc.language.isoenen
dc.subjectCancer Antibodiesen
dc.subject.meshAdult-
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshAntibodies, Neoplasm-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshDrug Administration Schedule-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshInfusions, Intravenous-
dc.subject.meshLymphoma, B-Cell-
dc.subject.meshLymphoma, Non-Hodgkin-
dc.subject.meshMale-
dc.subject.meshMycosis Fungoides-
dc.subject.meshRemission Induction-
dc.titleCAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.en
dc.typeArticleen
dc.contributor.departmentDepartment of Oncology, Karolinska Hospital, Stockholm, Sweden.en
dc.identifier.journalJournal of Clinical Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.